Amneal Pharmaceuticals held special shareholder meeting on Kashiv BioSciences deal

Shareholders also authorized issuance of 28,942,108 shares of common stock to the sellers in connection with the transaction; issuance remains contingent on closing.

An adjournment proposal was not put to a vote because the other items passed.

Closing is expected in the second half of 2026, subject to remaining conditions.

Amneal Pharmaceuticals held a special shareholder meeting on July 31, 2026 to vote on the proposed purchase of Kashiv BioSciences.

Shareholders adopted the transaction proposal, clearing the shareholder-approval condition for the Kashiv purchase agreement; the deal itself has not yet closed.